GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » WuXi Biologics (Cayman) Inc (OTCPK:WXXWY) » Definitions » Debt-to-Revenue

WuXi Biologics (Cayman) (WuXi Biologics (Cayman)) Debt-to-Revenue : 0.27 (As of Dec. 2023)


View and export this data going back to 2017. Start your Free Trial

What is WuXi Biologics (Cayman) Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

WuXi Biologics (Cayman)'s Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $102 Mil. WuXi Biologics (Cayman)'s Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $536 Mil. WuXi Biologics (Cayman)'s annualized Revenue for the quarter that ended in Dec. 2023 was $2,393 Mil. WuXi Biologics (Cayman)'s annualized Debt-to-Revenue for the quarter that ended in Dec. 2023 was 0.27.


WuXi Biologics (Cayman) Debt-to-Revenue Historical Data

The historical data trend for WuXi Biologics (Cayman)'s Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

WuXi Biologics (Cayman) Debt-to-Revenue Chart

WuXi Biologics (Cayman) Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.55 0.59 0.42 0.29 0.27

WuXi Biologics (Cayman) Semi-Annual Data
Dec14 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Debt-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.37 0.31 0.27 0.30 0.27

Competitive Comparison of WuXi Biologics (Cayman)'s Debt-to-Revenue

For the Biotechnology subindustry, WuXi Biologics (Cayman)'s Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


WuXi Biologics (Cayman)'s Debt-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, WuXi Biologics (Cayman)'s Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where WuXi Biologics (Cayman)'s Debt-to-Revenue falls into.



WuXi Biologics (Cayman) Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

WuXi Biologics (Cayman)'s Debt-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(102.421 + 536.407) / 2385.683
=0.27

WuXi Biologics (Cayman)'s annualized Debt-to-Revenue for the quarter that ended in Dec. 2023 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(102.421 + 536.407) / 2392.708
=0.27

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is two times the quarterly (Dec. 2023) Revenue data.


WuXi Biologics (Cayman) Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of WuXi Biologics (Cayman)'s Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


WuXi Biologics (Cayman) (WuXi Biologics (Cayman)) Business Description

Address
No. 108, Meiliang Road, Mashan Binhu District, Wuxi, CHN, 214092
WuXi Biologics is one of the largest global biologics CRDMOs. WuXi Biologics, incorporated in 2014 following the reorganization of WuXi PharmaTech, later known as WuXi AppTec, now has global revenue of CNY 15 billion. North American represented 55.6% of total revenue in 2022. It adopts the follow and win the molecule strategy by providing end-to-end services, from drug discovery to commercial manufacturing. It also adopts a global dual-sourcing strategy by providing drug products and large-scale drug substance manufacturing.